18060-42-9

Usage

Uses

Used in Pharmaceutical Industry:
6-fluoro-2-(4-methylphenyl)quinoline-4-carboxylic acid is used as a building block or intermediate for the synthesis of pharmaceuticals due to its potential pharmacological and biological activities. Its unique structure allows for the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
6-fluoro-2-(4-methylphenyl)quinoline-4-carboxylic acid is used as a building block or intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its chemical properties can be harnessed to create more effective and targeted agrochemicals, contributing to improved crop protection and yield.
Safety Considerations:
It is important to handle 6-fluoro-2-(4-methylphenyl)quinoline-4-carboxylic acid with caution and follow safety guidelines when working with it in laboratory settings. Proper protective equipment, such as gloves and eyewear, should be worn, and the chemical should be stored and disposed of according to recommended protocols to ensure the safety of researchers and the environment.

Upstream product

• 351-09-7 N-(4-fluorophenyl)-2-(hydroxyimino) acetamide 
• 443-69-6 5-fluoro-1H-indole-2,3-dione 
• 122-00-9 para-methylacetophenone 
• 2146-07-8 p-fluoroaniline hydrochloride 

Downstream Products

• 1453176-99-2 C₁₇H₁₁ClFNO 

Relevant academic research and scientific papers

Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy

The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC50 = 120 nM) was optimized to lead molecules with low nanomolar in vitro potency. Improvement of the pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED90 values below 1 mg/kg when dosed orally for 4 days. The favorable potency, selectivity, DMPK properties, and efficacy coupled with a novel mechanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498) to preclinical development.

A novel multiple-stage antimalarial agent that inhibits protein synthesis

There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a po

Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety

A series of novel bisquinoline derivatives connected by a 4-oxy-3-fluoroaniline moiety were synthesized and evaluated for their in vitro antitumour activities against a panel of five cancer cell lines (H460, HT-29, MKN-45, U87MG, and SMMC-7721). Most of compounds tested showed a potent activity and high selectivity towards the H460 and MKN-45 cell lines. Among the compounds tested, six (15d, 15e, 15m, 15n, 16a, and 16i) were further examined for their c-Met kinase activity; the compounds showed high efficacy with IC 50 values in the single-digit nM range. An analysis of structure-activity relationships indicated that an unsubstituted or a halogen-substituted phenyl ring on the 2-arylquinoline-4-carboxamide moiety was favourable for antitumour activity.